BPC-157: What the Evidence Actually Shows
What BPC-157 is, why the published research is almost entirely preclinical, its FDA and WADA status, and what the July 2026 advisory vote did not change.
BPC-157 is a synthetic peptide of 15 amino acids. The name stands for Body Protection Compound, and the sequence is a fragment of a larger protein originally isolated from human gastric juice.
It is one of the most searched compounds in the peptide space, and also one of the most poorly evidenced. Those two facts are worth holding together.
What the research actually consists of
The published literature on BPC-157 is substantial in volume and narrow in kind. The great majority of it is preclinical — rats and mice, with a smaller number of cell-culture studies. Reported findings cluster around tissue repair: tendon and ligament healing, muscle injury, gastrointestinal mucosal damage, and wound models.
Proposed mechanisms in that literature include effects on angiogenesis via the VEGFR2 pathway and interaction with the nitric oxide system. These are hypotheses generated in animals, not established mechanisms in humans.
The gap
What is missing is the part that matters for a person considering it: completed, adequately powered randomised controlled trials in humans. There is no established human dose, no characterised human pharmacokinetic profile in the public literature, and no long-term human safety data.
This is not a case of a promising compound awaiting a final confirmatory study. It is a compound whose entire evidence base sits at the stage that precedes human testing.
Positive results in rodents translate to humans a minority of the time across drug development generally. Animal data establishes a reason to run a human trial. It is not a substitute for one.
Regulatory status: a moving target
BPC-157’s legal position has changed several times, and reporting on it is often out of date.
| Date | What happened |
|---|---|
| September 2023 | FDA placed BPC-157 in Category 2 for 503A compounding — substances presenting significant safety risks |
| February 2026 | HHS announced an intention to revisit that classification |
| 23–24 July 2026 | The Pharmacy Compounding Advisory Committee reviewed seven peptides and recommended six for the 503A Bulks List |
At the July 2026 meeting the committee voted 8–6, with one abstention, to recommend BPC-157 for inclusion. TB-500, KPV, MOTS-c, Semax and Epitalon were also recommended; emideltide (DSIP) was the single rejection.
Three points are routinely lost in the coverage of that vote:
- It is advisory. The FDA is not bound by it and retains discretion to accept, modify or reject the recommendation.
- It changes nothing today. Formal rulemaking has to be completed first, a process typically measured in many months.
- Being eligible for compounding is not approval. A substance on the 503A Bulks List is one a pharmacist may compound on prescription — it is not a drug that has been through efficacy and safety review.
In sport: prohibited at all times
WADA added BPC-157 to the Prohibited List in 2022, under category S0, non-approved substances. S0 covers compounds with no current approval for human therapeutic use by any government health authority.
The practical consequences are strict: prohibited in and out of competition, with no therapeutic use exemption available. Sanctions have followed detection in tested athletes, and the compound has been found in products marketed as supplements — which is the route by which an athlete can encounter it without intending to.
What this means for record-keeping
If a compound has no established dose and no human pharmacokinetic profile, then what someone actually did — and when — is the only reliable record that exists. There is no reference schedule to compare against.
The same applies to handling. A compound with no official product document has no official storage instructions either — only the general stability principles that apply to peptides as a class.
PeptCycle keeps that record: what was administered, when, at what concentration, and what was observed alongside it — stored locally on the device, with no account and no server. It does not tell anyone what to take. It has no recommended doses anywhere, and it will not acquire any for a compound whose evidence base looks like this one’s.
Frequently asked questions
Is BPC-157 approved as a medicine?
No. BPC-157 is not approved for human therapeutic use by any national regulatory authority. It has no marketing authorisation in the United States, the European Union or elsewhere.
Does the July 2026 FDA advisory vote make BPC-157 legal to compound?
No. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend BPC-157 for the 503A Bulks List. That vote is advisory. The FDA still has to complete formal rulemaking, and until it does, the substance is not eligible for compounding under 503A.
Is BPC-157 banned in sport?
Yes. WADA added BPC-157 to the Prohibited List in 2022 under category S0, non-approved substances. It is prohibited at all times, in and out of competition, and no therapeutic use exemption is available for it.
How much human research exists?
Very little. The published body of work is overwhelmingly in rodents. There are no large completed randomised controlled trials in humans establishing efficacy or long-term safety for the indications the compound is discussed for.